Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | TERT | O14746 | 10/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4750130 | 0.98 | ALDH1A1 (0.70) | ALDH1A1POLBKMT2AMEN1LMNA | |
| SCHEMBL4749143 | 0.90 | ALDH1A1 (0.58) | ALDH1A1POLBKMT2AMEN1LMNA | |
| SCHEMBL5151404 | 0.87 | TP53 (0.74) | ALDH1A1LMNAMAPTTERT | |
| SCHEMBL4749808 | 0.85 | ATM (0.75) | POLBLMNAALOX15ATMTSHR | |
| SCHEMBL13149726 | 0.85 | KMT2A (0.97) | ALDH1A1POLBKMT2AMEN1LMNA | |
| SCHEMBL14619097 | 0.85 | KMT2A (0.76) | ALDH1A1POLBKMT2AMEN1LMNA | |
| SCHEMBL3012622 | 0.84 | ALDH1A1 (1.00) | ALDH1A1POLBKMT2AMEN1LMNA | |
| SCHEMBL22407743 | 0.84 | KDM4E (0.69) | ALDH1A1POLBKMT2AMEN1LMNA | |
| SCHEMBL4777614 | 0.84 | KDM4E (0.69) | ALDH1A1POLBKMT2AMEN1LMNA | |
| SCHEMBL24069015 | 0.84 | KMT2A (0.71) | ALDH1A1POLBKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008122667-A2 | UREYLENE DERIVATIVES | SCHOOL OF PHARMACY (GB) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122667-A2 | UREYLENE DERIVATIVES | SCHOOL OF PHARMACY (GB) | 2008-10-16 | — | — | WO | disclosed |
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| WO-2007018941-A2 | PYRIMIDYL-THIOPHENE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | AURKA, AURKC, AURKB | ALDH1A1 3516/4885POLB 1458/4885KMT2A 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.